
# Enum: StudyIdEnum




URI: [https://w3id.org/pcdc/model/StudyIdEnum](https://w3id.org/pcdc/model/StudyIdEnum)


## Other properties

|  |  |  |
| --- | --- | --- |

## Permissible Values

| Text | Description | Meaning | Other Information |
| :--- | :---: | :---: | ---: |
| AAML03P1 |  | ncit:C168936 |  |
| AAML0531 |  | ncit:C168937 |  |
| AAML1031 |  | ncit:C168938 |  |
| AMLBFM2004 |  | ncit:C168939 |  |
| AMLBFM2012 |  | ncit:C173250 |  |
| AMLBFM-Registry2012 |  | ncit:C173251 |  |
| AMLBFMRegistry2017 |  | ncit:C182031 |  |
| AMLBFM1998 |  | ncit:C182032 |  |
| SJCRHAML02 |  | ncit:C168940 |  |
| JPLSGAML05 |  | ncit:C168941 |  |
| AEIOPAML2002 |  | ncit:C168942 |  |
| JACLSAML99 |  | ncit:C168943 |  |
| DBAML01 |  | ncit:C168944 |  |
| MRCAML12 |  | ncit:C168945 |  |
| MRCAML15 |  | ncit:C173252 |  |
| NOPHOAML2004 |  | ncit:C168946 |  |
| NOPHOAML2012 |  | ncit:C173253 |  |
| PPLLSGAML98 |  | ncit:C173254 |  |
| AIEOPLAM92 |  | ncit:C173255 |  |
| SCFEELAM02 |  | ncit:C168947 |  |
| AHOD0831 |  | ncit:C185308 |  |
| AHOD0431 |  | ncit:C185310 |  |
| AHOD0031 |  | ncit:C185311 |  |
| AHOD1331 |  | ncit:C185312 |  |
| AHOD1221 |  | ncit:C185313 |  |
| AHOD03P1 |  | ncit:C185314 |  |
| AEWS1221 |  | ncit:C174968 |  |
| AEWS0331 |  | ncit:C174969 |  |
| AEWS0031 |  | ncit:C174970 |  |
| AEWS1031 |  | ncit:C174971 |  |
| EE99 |  | ncit:C174972 |  |
| EICESS92 |  | ncit:C174973 |  |
| AEWS07P1 |  | ncit:C174974 |  |
| AALL0331 | Standard Risk B-precursor Acute Lymphoblastic Leukemia (ALL) is a COG study from 2003-2011 | ncit:C178095 |  |
| AALL0232 | High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) is a COG study from 2003-2011 | ncit:C178065 |  |
| AALL0434 | Intensified Methotrexate, Nelarabine (Compound 506U78; IND # 52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia(ALL)or T-cell LymphoblasticLymphoma is a COG study from 2007-2014 | ncit:C178066 |  |
| AALL08B1 | Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) is a COG study from 2010-2018 | ncit:C178067 |  |
| AALL03B1 | Classification of Acute Lymphoblastic Leukemia is a COG study from 2003-2011 | ncit:C178068 |  |
| TGM85 |  | ncit:C177332 |  |
| TGM90 |  | ncit:C177333 |  |
| TGM95 |  | ncit:C177334 |  |
| GC1 |  | ncit:C113593 |  |
| GC2 |  | ncit:C177336 |  |
| GOG0078 |  | ncit:C177337 |  |
| GOG0090 |  | ncit:C177338 |  |
| GOG0116 |  | ncit:C177339 |  |
| P9749 |  | ncit:C177340 |  |
| POG9049 |  | ncit:C177341 |  |
| AGCT01P1 |  | ncit:C177342 |  |
| AGCT0132 |  | ncit:C177343 |  |
| AGCT0521 |  | ncit:C177344 |  |
| TE04 |  | ncit:C20299 |  |
| TE05 |  | ncit:C177346 |  |
| TE08 |  | ncit:C177347 |  |
| TE22 |  | ncit:C177348 |  |
| TE09 |  | ncit:C177349 |  |
| TE13 |  | ncit:C177350 |  |
| TE20 |  | ncit:C177351 |  |
| TIP |  | ncit:C90069 |  |
| TCGM2004 |  | ncit:C187201 |  |
| AOST0331/EURAMOS1 |  | ncit:C180361 |  |
| Sarcome13/OS2016 | A Multicentre, Randomised, Open-label, Phase II trial of MEPACT combined with post-operative chemotherapy for newly diagnosed high risk osteosarcoma patients (metastatic osteosarcoma at diagnosis or localized disease with poor histological response) | ncit:C180370 |  |
| OS2006 |  | ncit:C180367 |  |
| REGOBONE | A Randomized Phase II, placebo-controlled , multicenterstudy evaluating efficacy and safety of regorafenib inpatients with metastatic bone sarcomas | ncit:C180369 |  |
| P9754 |  | ncit:C180368 |  |
| INT133 | Trial of Adriamycin, Cisplatin and Methotrexate With and Without Ifosfamide, With and Without Muramyl Tripeptide Phosphatidyl Ethanolamine (MTP-PE) for Treatment of Osteogenic Sarcoma | ncit:C180366 |  |
| AOST0221 |  | ncit:C180360 |  |
| AOST0121 |  | ncit:C180358 |  |
| AOST01P1 |  | ncit:C180359 |  |
| AOST1321 |  | ncit:C180362 |  |
| AOST1421 |  | ncit:C180363 |  |
| CCG-7942 |  | ncit:C180365 |  |
| CCG-782 |  | ncit:C180364 |  |

